Supplementary Materials

Supplementary Material for:

A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection

Michael C. Sneller, J. Shawn Justement, Kathleen R. Gittens, Mary E. Petrone, Katherine E. Clarridge, Michael A. Proschan, Richard Kwan, Victoria Shi, Jana Blazkova, Eric W. Refsland, Daryl E. Morris, Kristen W. Cohen, M. Juliana McElrath, Rong Xu, Michael A. Egan, John H. Eldridge, Erika Benko, Colin Kovacs, Susan Moir, Tae-Wook Chun,* Anthony S. Fauci

*Corresponding author. Email: twchun{at}nih.gov

Published 6 December 2017, Sci. Transl. Med. 9, eaan8848 (2017)
DOI: 10.1126/scitranslmed.aaan8848

This PDF file includes:

  • Fig. S1. Plasma viremia of individual study subjects after discontinuation of ART.
  • Fig. S2. Gating strategy for ICS by flow cytometry.
  • Fig. S3. Kinetics of HIV-specific T cell responses and immune parameters in placebo and vaccine recipients.
  • Fig. S4. Detection of anti-VSV antibody in study subjects who received therapeutic vaccines.
  • Table S1. Vaccine-related AEs.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S2. (Microsoft Excel format). Primary data.